Table 5.
Documented treatment-emergent all-grade adverse events in ≥ 10% of patients (safety population)
| L (n = 13) | L + R (n = 11) | L + other (n = 34) | Overall (N = 58) | |||||
|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | No. | % | |
| Hematologic | ||||||||
| Anemia | 2 | 15 | 3 | 27 | 5 | 15 | 10 | 17 |
| Thrombocytopenia | 1 | 8 | 1 | 9 | 7 | 21 | 9 | 16 |
| Neutropenia | 1 | 8 | 1 | 9 | 6 | 18 | 8 | 14 |
| Pancytopenia | 1 | 8 | 3 | 27 | 3 | 9 | 7 | 12 |
| Febrile neutropenia | 0 | 0 | 0 | 0 | 6 | 18 | 6 | 10 |
| Nonhematologic | ||||||||
| Fatigue | 4 | 31 | 4 | 36 | 14 | 41 | 22 | 38 |
| Nausea | 2 | 15 | 2 | 18 | 7 | 21 | 11 | 19 |
| Dizziness | 2 | 15 | 2 | 18 | 7 | 21 | 11 | 19 |
| Dyspnea | 2 | 15 | 3 | 27 | 6 | 18 | 11 | 19 |
| Peripheral edema | 0 | 0 | 2 | 18 | 9 | 26 | 11 | 19 |
| Rash | 2 | 15 | 1 | 9 | 7 | 21 | 10 | 17 |
| Cough | 1 | 8 | 3 | 27 | 7 | 21 | 11 | 19 |
| Decreased appetite | 2 | 15 | 0 | 0 | 5 | 15 | 7 | 12 |
| Diarrhea | 0 | 0 | 1 | 9 | 7 | 21 | 8 | 14 |
| Headache | 3 | 23 | 1 | 9 | 2 | 6 | 6 | 10 |
| Pyrexia | 1 | 8 | 0 | 0 | 5 | 15 | 6 | 10 |
| Vomiting | 0 | 0 | 2 | 18 | 4 | 12 | 6 | 10 |
| Constipation | 0 | 0 | 0 | 0 | 6 | 18 | 6 | 10 |
| Laboratory investigations | ||||||||
| Platelet count decreased | 2 | 15 | 1 | 9 | 3 | 9 | 6 | 10 |
| White blood cell count decreased | 1 | 8 | 1 | 9 | 4 | 12 | 6 | 10 |
L lenalidomide, L + R lenalidomide plus rituximab